SCHEMBL24147477

SCHEMBL24147477

CNc1nc(Nc2cn([C@@](C)(C#N)CF)nc2C)ncc1C(F)(F)F

nearest known ligand 0.78

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 20/20 0.78
CYP1A2 P05177 6/20 0.78
TTK P33981 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24146920 1.00 LRRK2 (0.78) LRRK2CYP1A2TTK
SCHEMBL24147024 1.00 LRRK2 (0.78) LRRK2CYP1A2TTK
SCHEMBL16469355 0.92 LRRK2 (0.78) LRRK2CYP1A2TTK
SCHEMBL24147267 0.90 LRRK2 (0.65) LRRK2CYP1A2TTK
SCHEMBL24147457 0.90 LRRK2 (0.65) LRRK2CYP1A2TTK
SCHEMBL24146954 0.90 LRRK2 (0.65) LRRK2CYP1A2TTK
SCHEMBL24147251 0.88 LRRK2 (0.60) LRRK2CYP1A2TTK
SCHEMBL24146928 0.88 LRRK2 (0.60) LRRK2CYP1A2TTK
SCHEMBL24147264 0.88 LRRK2 (0.60) LRRK2CYP1A2TTK
Dnl-201 SCHEMBL4561063 0.88 LRRK2 (1.00) LRRK2CYP1A2TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119371-A1 COMPOUND, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2022-04-21 US disclosed
US-11214565-B2 Compound, compositions, and methods DENALI THERAPEUTICS INC. (US) 2022-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119371-A1 COMPOUND, COMPOSITIONS, AND METHODS LRRK2, PARK7, SNCA LRRK2 1/4885CYP1A2 3146/4885TTK 929/4885
US-11214565-B2 Compound, compositions, and methods LRRK2, PARK7, MAPT LRRK2 1/4885CYP1A2 3151/4885TTK 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.